Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hospital Universitari Vall d'Hebron Research Institute
With
Hospital Vall d'Hebron
Hospital Sant Joan de Deu
Hospital de Cruces
Parc Sanitari Sant Joan de Déu
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Pregnant women ≥18 years
Gestational age \< 14 weeks at randomisation
One or more of the following complications in a previous pregnancy:
* Severe PE resulting in delivery before 32 weeks of gestation
* Newborn weight less than the 10th percentile and documented abnormal Doppler in the umbilical artery during pregnancy before 32 weeks gestation
* Abruption of placenta
* Unexplained intrauterine death between 20-41,6 weeks of gestation secondary of placental insufficiency or
Uterine arteries Pulsatility Index (mPI) Doppler ≥95th percentile at 11-14 weeks of gestation.
You may not be if
Multiple pregnancy
Abnormal thrombophilia study
Alcohol or illicit drug use
Severe fetal malformations or chromosomal abnormalities
Previous history of infertility ( 3 or more early miscarriages)
Maternal HIV, Cytomegalovirus or toxoplasma infection
Known fetal abnormality or chromosomal defect at randomisation
Women with previous venous or arterial thrombotic event
Organic lesions that could increase the hemorrhagic risk: gastric ulcus, stroke, a recent hemorrhagic event, high risk situations for hemorrhagic event
Known allergy to heparin or LMWH, thrombopenia or thrombosis episode due to heparin treatment
Contraindication to LMWH
An absolute indication for anticoagulant therapy: venous deep thrombosis, pulmonary embolism, ovaric hyperestimulation, cardiophaty, others
Metabolic disorders a risk for development of PE and/or IUGR: Type I diabetes, hipertiroidism, chronic renal insufficiency
Clareo Health | Low Weight Heparin prOphylaxis for Placental-Mediated Complications of PrEgnancy
